Abstract
Development of Pneumocystis pneumonia (PCP) is a common problem among immunosuppressed individuals. There are windows of opportunity in which vaccination would be beneficial, but to date, no vaccines have made it to clinical trials. Significant hurdles to vaccine development include host range specificity, making it difficult to translate from animal models to humans. Discovery of cross-reactive epitopes is critical to moving vaccine candidates from preclinical animal studies to clinical trials.
Document Type
Commentary
Publication Date
4-2017
Digital Object Identifier (DOI)
https://doi.org/10.1128/IAI.00035-17
Funding Information
This work was supported in part by grant AI118818 from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, U.S. Department of Health and Human Services.
Repository Citation
Garvy, Beth A., "Overcoming Hurdles to Development of a Vaccine Against Pneumocystis jirovecii" (2017). Microbiology, Immunology, and Molecular Genetics Faculty Publications. 97.
https://uknowledge.uky.edu/microbio_facpub/97
Included in
Immunology and Infectious Disease Commons, Medical Immunology Commons, Medical Microbiology Commons, Molecular Genetics Commons
Notes/Citation Information
Published in Infection and Immunity, v. 85, issue 4, e00035-17, p. 1-4.
Copyright © 2017 American Society for Microbiology. All Rights Reserved.
The copyright holder has granted the permission for posting the article here.